Refractory Lung Non-Small Cell Carcinoma
6 clinical trials · Condition
◉ Watch Refractory Lung Non-Small Cell Carcinoma
| Record | Firm | Date |
|---|---|---|
| Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors (NCT05334329) | University of California, Irvine | 2022-07-20 |
| Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer (NCT04285671) | Jonsson Comprehensive Cancer Center | 2021-01-29 |
| Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors (NCT04007744) | Mayo Clinic | 2020-02-13 |
| Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC (NCT04081688) | Rutgers, The State University of New Jersey | 2019-09-11 |
| Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer (NCT03600701) | National Cancer Institute (NCI) | 2018-11-29 |
Track Refractory Lung Non-Small Cell Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.